Biotechnology
PHASE Scientific Launches World's Largest Urine-Based Cervical Cancer (HPV) Screening Clinical Study, Marking New Era of Non-Invasive Cervical Cancer Screening
GUANG'AN, China, Sept. 22, 2025 /PRNewswire/ -- PHASE Scientific International Limited ("PHASE Scientific") today announced the official launch of the world's largest clinical study for urine-based cervical cancer (HPV) screening, with the first site established in Guang'an,Sichuan Province, Chin...
2025-09-22 15:39
1907
Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer
HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independently developed TIGIT/TGF-β bifunctional antibody fusion protein, in combination with ivonescimab ...
2025-09-22 14:51
1366
First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
NANJING, China, Sept. 22, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New Drug (IND) application for LBL-047 onSeptember 19, ...
2025-09-22 12:29
1811
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, d...
2025-09-22 08:00
1543
Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025
SHANGHAI and HONG KONG, Sept. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic m...
2025-09-19 20:00
2389
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg...
2025-09-19 19:59
2602
Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabol...
2025-09-19 18:01
2408
DarwinCell Showcases novel MSC-based drug ALT001 at the 150th American Neurological Association Annual Meeting
BALTIMORE, Sept. 19, 2025 /PRNewswire/ -- The 150th American Neurological Association Annual Meeting (ANA 2025) was successfully held inBaltimore, USA, fromSeptember 13 to 16, 2025. The conference brought together leading global experts, scholars, and industry leaders in the field of neuroscience...
2025-09-19 17:28
1885
Lenovo GOAST 4.0 Decodes Trillions of Cells, Accelerating Genome Analysis to 24 Minutes
Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries SINGAPORE, Sept. 19, 2025 /PRNewswire/ -- Lenovo today shared updates on the 4th generation of its Genomics Optimization and Scalability Tool –GOAST v4.0. Since its...
2025-09-19 16:58
1807
Lenovo GOAST 4.0 Decodes Trillions of Cells, Accelerating Genome Analysis to 24 Minutes
Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries CANBERRA, Australia, Sept. 19, 2025 /PRNewswire/ -- Lenovo today shared updates on the 4th generation of its Genomics Optimization and Scalability Tool –GOAST v4.0....
2025-09-19 16:51
1705
Lenovo GOAST 4.0 Decodes Trillions of Cells, Accelerating Genome Analysis to 24 Minutes
Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries MANILA, Philippines, Sept. 19, 2025 /PRNewswire/ -- Lenovo today shared updates on the 4th generation of its Genomics Optimization and Scalability Tool –GOAST v4.0....
2025-09-19 16:04
1807
2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment
SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 18, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that the 36-month long-term foll...
2025-09-19 09:39
1961
QL Biopharm reports Phase 2 results of a monthly dose study evaluating zovaglutide, a novel, extended half-life GLP-1 receptor agonist at EASD 2025
* Patients who received zovaglutide at a once-monthly dose of 160 mg experienced a 13.8% reduction in body weight at 24 weeks, highly comparable to reductions observed in patients who received 80 mg every other week (12.5%) * The overall safety and tolerability of zovaglutide were consistent ...
2025-09-18 21:00
1656
Beyond Ventures Champions HKIC's new initiatives outlined in The Policy Address 2025
Strategic partnership with the HKIC fuels growth across biotech, hardcore and greentech sectors, reinforcingHong Kong's role as a super-connector and super value-adder in the global innovation landscape HONG KONG, Sept. 18, 2025 /PRNewswire/ -- Hong Kong-based venture capital firm Beyond Venture...
2025-09-18 17:57
1966
Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabol...
2025-09-18 12:00
1719
Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway
Meaningful improvements confirmed in slow-progressor subgroup; biomarker reductions support precision-medicine approach and potential FDA accelerated pathway SEOUL, South Korea, Sept. 17, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key findings...
2025-09-18 10:28
1717
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
YANTAI, China, Sept. 18, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by Reme...
2025-09-18 09:00
1760
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, R&D code...
2025-09-18 08:15
1990
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo. --Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events (TEAEs)...
2025-09-18 07:30
1672
MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.
* First-ever clinical data supporting safety and efficacy of in vivo CAR-T Therapy in refractory systemic lupus erythematosus (SLE) patients. * Data shows low dose of HN2301 reprogrammed up to 60% of CD8+ CAR+ T-cells in the peripheral blood of patients, resulting in complete depletion of cir...
2025-09-18 05:09
1429
Week's Top Stories
Most Reposted
Tonik raises US$12M Pre-Series C to scale capital-efficient lending in the Philippines
[Picked up by 318 media titles]
2025-12-04 10:15
Hyundai Motor Group and Air Liquide Advance Global Partnership to Accelerate Hydrogen Ecosystem
[Picked up by 311 media titles]
2025-12-04 16:00
Klook takes the lead among international travelers booking paid tours and activities in Japan
[Picked up by 309 media titles]
2025-12-04 13:12
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 297 media titles]
2025-12-03 09:00
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4446
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3626
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3604
PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results
2025-12-05 21:45
3408